Lifecore Biomedical (NASDAQ:LFCR) is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.
The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care. Lifecore supplies sterile injectable HA solutions used in viscoelastic applications for cataract and other eye surgeries, viscosupplementation for joint disorders and HA gels for soft-tissue augmentation and dermal therapies. In addition, its research and development team works on advanced cross-linking technologies to improve product longevity and biocompatibility.
Beyond its own branded offerings, Lifecore provides contract development and manufacturing services to global customers in the pharmaceutical, medical device and aesthetic industries. Its FDA-registered, GMP-compliant facility in Minnesota supports process development, scale-up and commercial production of HA and related biopolymers. Lifecore’s integrated services enable partners to accelerate time-to-market for novel formulations and medical devices.
Founded in 1993, Lifecore has grown from a single-product developer to a diversified HA specialist serving markets in North America, Europe and Asia. The company is led by President and Chief Executive Officer Erin Tagge, who has more than 20 years of experience in biopharmaceutical development and manufacturing. Under her leadership, Lifecore continues to invest in quality systems, research collaborations and facility expansions to support long-term growth.
